Reviparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Reviparin
Accession Number
DB09259
Type
Small Molecule
Groups
Approved, Investigational
Description

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.[1] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.[2] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[3]

Synonyms
  • Reviparin sodium
Categories
UNII
5R0L1D739E
CAS number
9041-08-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.[3]

Pharmacodynamics

Reviparin is been shown to present significant inhibition of smooth muscle cell migration and proliferation in human cell cultures without affecting endothelial cell growth.[1]

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Reviparin.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Reviparin.
AcebutololThe risk or severity of hyperkalemia can be increased when Reviparin is combined with Acebutolol.
AceclofenacAceclofenac may increase the anticoagulant activities of Reviparin.
AcemetacinThe risk or severity of bleeding can be increased when Reviparin is combined with Acemetacin.
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Reviparin.
Acetylsalicylic acidThe risk or severity of bleeding can be increased when Reviparin is combined with Acetylsalicylic acid.
AlclofenacAlclofenac may increase the anticoagulant activities of Reviparin.
AliskirenReviparin may increase the hyperkalemic activities of Aliskiren.
AllylestrenolThe therapeutic efficacy of Reviparin can be decreased when used in combination with Allylestrenol.
Food Interactions
Not Available

References

General References
  1. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 1996 Nov 15;28(6):1437-43. [PubMed:8917255]
  2. Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol. 2000 Apr;49(4):337-41. [PubMed:10759689]
  3. FDA orphan list [Link]
External Links
KEGG Drug
D03337
PubChem Substance
347910423
Wikipedia
Reviparin_sodium
ATC Codes
B01AB08 — Reviparin
MSDS
Download (52.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentNeoplasms / Venous Thromboembolism (VTE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility50 mg/ml'MSDS'
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 10:53 / Updated on October 01, 2018 14:49